Pipeline Olive
| Pathway | Program | Indication(s) | Discovery | Pre-Clinical | Clinical | Next Milestone |
Rights* |
|---|---|---|---|---|---|---|---|
| |
|||||||
| IL–1R/ TLR |
IRAK4 | HS (Focus), AD, RA, Others | KT-474 |  |
|||
| Next Generation |  |
||||||
| IRAKIMiD (IRAK4, Ikaros, Aiolos) |
MYD88 MT DLBCL |
|
|||||
| JAK/ STAT |
STAT3 | Liquid, Solid Tumors |
|
||||
| STAT3 | Autoimmune, Fibrotic Diseases | |
|||||
| |
|||||||
| Pegasus Platform | Internal | Leveraging the capabilities of our Pegasus platform, we are advancing multiple degrader programs in immunology-inflammation and genetically defined oncology indications | |
||||
| Partnered | Our strategic collaboration with Sanofi includes a degrader program targeting IRAK4 and a second earlier stage program | |
|||||
| Our strategic collaboration with Vertex is focused on the research and development of degraders against at least 6 targets in disease areas outside of our core strategic focus of immunology-inflammation and oncology |  |
||||||
| |
|||||||
Oncology
Immunology-Inflammation
*Kymera retains the option to participate in U.S. development and commercialization for Sanofi-partnered programs.
| Pathway | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IL-1R/TLR | ||||||||||||||||||
| Program | Indication(s) | Rights* | ||||||||||||||||
| |
||||||||||||||||||
| IRAK4 | HS (Focus), AD, RA, Others | |
||||||||||||||||
|
||||||||||||||||||
| IRAKIMiD (IRAK4, Ikaros, Aiolos) | MYD-88 MT DLBCL | |
||||||||||||||||
|
||||||||||||||||||
| Pathway | ||||||||||||||||||
| JAK/STAT | ||||||||||||||||||
| Program | Indication(s) | Rights* | ||||||||||||||||
| |
||||||||||||||||||
| STAT3 | Liquid,Solid Tumors | |
||||||||||||||||
|
||||||||||||||||||
| STAT3 | Autoimmune, Fibrotic Diseases | |
||||||||||||||||
|
||||||||||||||||||
| |
||||||||||||||||||
| Pathway | ||||||||||||||||||
| Pegasus Platform | ||||||||||||||||||
| Program | Indication(s) | Rights* | ||||||||||||||||
| |
||||||||||||||||||
| Internal | Leveraging the capabilities of our Pegasus platform, we are advancing multiple degrader programs in immunology-inflammation and genetically defined oncology indications | |
||||||||||||||||
| Partnered | Our strategic collaboration with Sanofi includes a degrader program targeting IRAK4 and a second earlier stage program | |
||||||||||||||||
| Our strategic collaboration with Vertex is focused on the research and development of degraders against at least 6 targets in disease areas outside of our core strategic focus of immunology-inflammation and oncology | |
|||||||||||||||||
| |
||||||||||||||||||
Oncology
Immunology-Inflammation
*Kymera retains the option to participate in U.S. development and commercialization for Sanofi-partnered programs.